Personal information

Emails & domains

Verified email domains

Other IDs

ResearcherID: P-2569-2014

Activities

Collapse all

Employment (1)

University of Pennsylvania: Philadelphia, PA, US

PI
Employment
Source: check_circle
University of Pennsylvania via ORCID Member Portal

Works (50 of 53)

Items per page:
Page 1 of 2

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

2025-01-16 | Other
DOI: 10.1093/neuonc/noaf012
Contributors: John Maris; Nathan M. Kendsersky; Michal Odrobina; Nathaniel W. Mabe; Alvin Farrel; Liron Grossmann; Matthew Tsang; David Groff; Adam J. Wolpaw; Alaa Narch et al.
Source: check_circle
Crossref

Advancing childhood cancer research through young investigator and advocate collaboration

Pediatric Blood & Cancer
2024-09 | Journal article
DOI: 10.1002/pbc.31127
Contributors: Amber K. Weiner; Antonia Palmer; Melanie Frost Moll; Gavin Lindberg; Kevin Reidy; Sharon J. Diskin; Crystal L. Mackall; John M. Maris; Patrick J. Sullivan
Source: check_circle
Crossref

IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy

2024-06-06 | Preprint
DOI: 10.1101/2024.06.04.597422
Contributors: Rawan Shraim; Brian Mooney; Karina L. Conkrite; Amber K. Weiner; Gregg B. Morin; Poul H. Sorensen; John M. Maris; Sharon J. Diskin; Ahmet Sacan
Source: check_circle
Crossref

Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single‐center retrospective study

Pediatric Blood & Cancer
2024-04 | Journal article
DOI: 10.1002/pbc.30887
Contributors: Sean Schoeman; Rochelle Bagatell; Anne Marie Cahill; John Maris; Peter Mattei; Yael Mosse; Jennifer Pogoriler; Abhay Srinivasan; Michael Acord
Source: check_circle
Crossref

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131I‐MIBG in patients with relapsed/refractory neuroblastoma

Pediatric Blood & Cancer
2024-01 | Journal article
DOI: 10.1002/pbc.30743
Contributors: Vandana Batra; Ajami Gikandi; Bruce Pawel; Daniel Martinez; M. Meaghan Granger; Araz Marachelian; Julie R. Park; John M. Maris; Kieuhoa T. Vo; Katherine K. Matthay et al.
Source: check_circle
Crossref

Advancing childhood cancer research through young investigator and advocate collaboration

2023-12-05 | Preprint
DOI: 10.1101/2023.12.03.569769
Contributors: Amber K. Weiner; Antonia Palmer; Melanie Frost Moll; Gavin Lindberg; Kevin Reidy; Sharon J. Diskin; Crystal L. Mackall; John M. Maris; Patrick J. Sullivan
Source: check_circle
Crossref

Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification

Journal of Clinical Oncology
2023-06-10 | Journal article
DOI: 10.1200/JCO.22.01946
Contributors: Hannah G. Bender; Meredith S. Irwin; Michael D. Hogarty; Robert Castleberry; John M. Maris; Pei-Chi Kao; Fan F. Zhang; Arlene Naranjo; Susan L. Cohn; Wendy B. London
Source: check_circle
Crossref

In memoriam: Dr. Audrey E. Evans

Pediatric Blood & Cancer
2023-03 | Journal article
DOI: 10.1002/pbc.30113
Contributors: John M. Maris
Source: check_circle
Crossref

Data from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530348.v1
Contributors: Kristina A. Cole; Sharmistha Pal; Rachel A. Kudgus; Heba Ijaz; Xiaowei Liu; Charles G. Minard; Bruce R. Pawel; John M. Maris; Daphne A. Haas-Kogan; Stephan D. Voss et al.
Source: check_circle
Crossref

Data from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530348
Contributors: Kristina A. Cole; Sharmistha Pal; Rachel A. Kudgus; Heba Ijaz; Xiaowei Liu; Charles G. Minard; Bruce R. Pawel; John M. Maris; Daphne A. Haas-Kogan; Stephan D. Voss et al.
Source: check_circle
Crossref

Data from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527279
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Data from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6527279.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Data from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.c.6511223
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Data from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.c.6511223.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469519
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469519.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469516
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469516.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Figure Legends from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469513
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Figure Legends from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469513.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469510
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469510.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469507
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22469507.v1
Contributors: Steven G. DuBois; Yael P. Mosse; Elizabeth Fox; Rachel A. Kudgus; Joel M. Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M. Maris; Clare J. Twist et al.
Source: check_circle
Crossref

Supplemental Tables S1-5 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422452.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplemental Tables S1-5 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422452
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure Legends from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422449
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure Legends from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422449.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S1 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422446.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S1 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422446
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S2 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422443
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S2 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422443.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S3 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422440
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S3 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422440.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S4 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422434
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S4 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422434.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S5 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422431
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S5 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422431.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S6 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422428.v1
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Supplementary Figure S6 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

2023-03-31 | Preprint
DOI: 10.1158/0008-5472.22422428
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref

Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480001.v1
Contributors: Kristina A. Cole; Sharmistha Pal; Rachel A. Kudgus; Heba Ijaz; Xiaowei Liu; Charles G. Minard; Bruce R. Pawel; John M. Maris; Daphne A. Haas-Kogan; Stephan D. Voss et al.
Source: check_circle
Crossref

Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480001
Contributors: Kristina A. Cole; Sharmistha Pal; Rachel A. Kudgus; Heba Ijaz; Xiaowei Liu; Charles G. Minard; Bruce R. Pawel; John M. Maris; Daphne A. Haas-Kogan; Stephan D. Voss et al.
Source: check_circle
Crossref

Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma

British Journal of Cancer
2022-11-23 | Journal article
DOI: 10.1038/s41416-022-01988-z
Contributors: H. Lalchungnunga; Wen Hao; John M. Maris; Shahab Asgharzadeh; Kai-Oliver Henrich; Frank Westermann; Deborah A. Tweddle; Edward C. Schwalbe; Gordon Strathdee
Source: check_circle
Crossref

In memoriam: Dr. Audrey E. Evans

2022-10-14 | Preprint
DOI: 10.22541/au.166574350.05326142/v1
Contributors: John Maris
Source: check_circle
Crossref

Genetic Analysis in African American Children Supports Ancestry-Specific Neuroblastoma Susceptibility

Cancer Epidemiology, Biomarkers & Prevention
2022-04-01 | Journal article
DOI: 10.1158/1055-9965.EPI-21-0782
Contributors: Alessandro Testori; Zalman Vaksman; Sharon J. Diskin; Hakon Hakonarson; Mario Capasso; Achille Iolascon; John M. Maris; Marcella Devoto
Source: check_circle
Crossref

DNMT3A overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults

Blood
2022-01-20 | Journal article
DOI: 10.1182/blood.2021014052
Contributors: Margaret A. Ferris; Amanda M. Smith; Sharon E. Heath; Eric J. Duncavage; Matthew Oberley; David Freyer; Robert Wynn; Sofia Douzgou; John M. Maris; Anne F. Reilly et al.
Source: check_circle
Crossref

Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles

Molecular Oncology
2021-02 | Journal article
DOI: 10.1002/1878-0261.12880
Contributors: Liron D. Grossmann; John M. Maris
Source: check_circle
Crossref

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity

Cell Reports Medicine
2020-06 | Journal article
DOI: 10.1016/j.xcrm.2020.100036
Contributors: Mark Yarmarkovich; John M. Warrington; Alvin Farrel; John M. Maris
Source: check_circle
Crossref

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Clinical Cancer Research
2020-03-15 | Journal article
DOI: 10.1158/1078-0432.CCR-19-3470
Contributors: Kristina A. Cole; Sharmistha Pal; Rachel A. Kudgus; Heba Ijaz; Xiaowei Liu; Charles G. Minard; Bruce R. Pawel; John M. Maris; Daphne A. Haas-Kogan; Stephan D. Voss et al.
Source: check_circle
Crossref

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

Cancer Research
2019-12-15 | Journal article
DOI: 10.1158/0008-5472.CAN-19-1415
Contributors: Grace E. Coggins; Alvin Farrel; Komal S. Rathi; Colin M. Hayes; Laura Scolaro; Jo Lynne Rokita; John M. Maris
Source: check_circle
Crossref
Items per page:
Page 1 of 2
How many people are using ORCID?